Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

PARP inhibitors and their evolving role for the treatment of prostate cancer

Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
PARP inhibitors and their evolving role for the treatment of prostate cancer ( Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi )
24 Sep 2020

Disparities in access to oncology clinical trials across Europe

Prof Ana Carneiro - Lund University, Lund, Sweden
Disparities in access to oncology clinical trials across Europe ( Prof Ana Carneiro - Lund University, Lund, Sweden )
24 Sep 2020

ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated mTNBC

Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated mTNBC ( Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA )
23 Sep 2020

ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer patients

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
ALTA-1L: Brigatinib vs crizotinib for ALK  advanced non small cell lung cancer patients ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
23 Sep 2020

Breast cancer roundup from ESMO 2020

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer roundup from ESMO 2020 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
23 Sep 2020

OncoAlert and ecancer weekly roundup for September 14-19, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for September 14-19, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
23 Sep 2020

IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer

Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer ( Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA )
22 Sep 2020

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection

Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection ( Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan )
22 Sep 2020

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004 ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
22 Sep 2020

CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers

Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers ( Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany )
22 Sep 2020

AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
22 Sep 2020

Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC

Dr Alex Spira and Dr Joshua Sabari
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC ( Dr Alex Spira and Dr Joshua Sabari )
21 Sep 2020